AgeX Therapeutics

AgeX is not an investment firm. It is a publicly traded biotechnology company. Capital allocation decisions — research priorities, clinical pipeline funding, and corporate development — are made by the CEO, Michael West, and the board of directors, consistent with public-company governance.

Michael West founded Geron Corporation in 1990 and later co-founded BioTime in 2001. AgeX was spun out of BioTime in 2017 as a subsidiary focused specifically on the therapeutic application of pluripotent stem cells and telomerase biology. In 2019, BioTime distributed AgeX shares to its shareholders, fully separating the companies. BioTime later rebranded to Lineage Cell Therapeutics.

No. AgeX is a publicly traded biotech (NYSE American: AGE). There is no single-family wealth behind the firm. The founding wealth comes from the scientific intellectual property developed by Michael West and his teams, funded through standard biotech equity raises and public-company mechanics.

AgeX operates two platforms: PureStem, which produces clonal embryonic progenitor cell lines to regenerate young tissue, and UniverCyte, which uses human leukocyte antigen engineering to create universal donor stem cells. Both aim at diseases of aging, not cosmetic longevity or wellness services.

AgeX funds operations through public equity raises, warrant exercises, and occasional grant or collaboration revenue. As a micro-cap public company, it does not charge management fees or accept LP commitments, unlike a venture fund or institutional asset manager. The 2023 merger with Serina Therapeutics brought a second platform and additional research assets.